Meaningful reductions in core operating costs expected
We expect this review to result in meaningful savings in our core operating costs that will benefit our financial performance. The review will be conducted expeditiously and will be led by a special committee of our independent directors. The Board expects to provide shareholders with detailed outcomes of the review in the third quarter of 2017.
The Board remains confident in the Company’s long-term plans for revenue and profit growth, and remains fully committed to delivering attractive returns for shareholders.
The Annual Stockholders Meeting is now just days away. We urge our shareholders to vote on the WHITE proxy card in favor of the current Board of Directors to protect their investment and the long-term value of
ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies.
This press release contains certain “forward-looking” statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives and future events, including expected cost savings.
Senior Vice President and Chief Financial Officer
email@example.com or firstname.lastname@example.org